Xcovery
is a Florida-based biopharmaceutical company that develops and commercializes ALK kinase inhibitors for the treatment of cancer... Read moreXcovery
is a Florida-based biopharmaceutical company that develops and commercializes ALK kinase inhibitors for the treatment of cancer... Read more
News
Apr 27, 2026
StreetInsider
Press Release: Xcovery : Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
Dec 21, 2024
Medthority
Xcovery: FDA Approves Ensacove for ALK-Positive Lung Cancer
Mar 19, 2024
Medthority
Xcovery: FDA accepts NDA for ensartinib (X-396) for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer
Mar 14, 2024
Pharamceutical Technology
Xcovery: Xcovery edges closer to FDA approval for NSCLC ALK inhibitor
Mar 13, 2024
Business Wire
Xcovery: U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib
Feb 23, 2023
Pharamceutical Technology
Xcovery: Vorolanib by Xcovery Holding for Small-Cell Lung Cancer: Likelihood of Approval
May 24, 2022
FirstWord Pharma
Xcovery: Xcovery SHP2 Inhibitor IND Approved by US FDA
Mar 29, 2022
Medthority
Xcovery: NMPA (China) approves ensartinib to treat first line ALK positive NSCLC.
Mar 23, 2022
StreetInsider
Press Release: Xcovery : Ensartinib Secured Its First Approval for 1st Line Treatment in ALK+ NSCLC
Dec 07, 2021
ChinaBio Today
Xcovery: Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx
Xcovery Competitors
1
2
3
4
5
6
7
8
9
10